0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Successful Treatment of Cerebral Mucormycosis with Amphotericin B

Gerard N. Burrow, MD; Robert B. Salmon, MD; James P. Nolan, MD
JAMA. 1963;183(5):370-372. doi:10.1001/jama.1963.63700050034023a.
Text Size: A A A
Published online

RECENT REPORTS of recovery from mucormycosis following the appropriate therapy1,2 have stimulated renewed interest in the disease. Mucormycosis is caused by tissue invasion of saprophytic fungi of the genus Mucor. The disease occurs in patients who have debilitating diseases, or who have received antibiotics, steroids, or anti-tumor agents, and is particularly prone to develop in patients with diabetic acidosis. Forty-two percent of the cases in a recent review of mucormycosis3 were diabetic. Cerebral mucormycosis, the most common form of the disease, is associated with an extremely high mortality. Only six survivals1,4-7 have been reported, and all of those described have been left with residual deficits (see table).

The present case is of interest because the diagnosis was made early on the basis of certain previously described criteria8,9 and therapy begun with amphotericin B. Despite disturbing side effects of the drug, therapy was continued, and the patient

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();